Raxibacumab: potential role in the treatment of inhalational anthrax

Carlos E Kummerfeldt
Division of Pulmonary, Critical Care, Allergy and Sleep Medicine, Medical University of South Carolina, Charleston, SC, USA

Abstract: Anthrax is a highly contagious and potentially fatal human disease caused by *Bacillus anthracis*, an aerobic, Gram-positive, spore-forming rod-shaped bacterium with worldwide distribution as a zoonotic infection in herbivore animals. Bioterrorist attacks with inhalational anthrax have prompted the development of more effective treatments. Antibodies against anthrax toxin have been shown to decrease mortality in animal studies. Raxibacumab is a recombinant human monoclonal antibody developed against inhalational anthrax. The drug received approval after human studies showed its safety and animal studies demonstrated its efficacy for treatment as well as prophylaxis against inhalational anthrax. It works by preventing binding of the protective antigen component of the anthrax toxin to its receptors in host cells, thereby blocking the toxin’s deleterious effects. Recently updated therapy guidelines for *Bacillus anthracis* recommend the use of antitoxin treatment. Raxibacumab is the first monoclonal antitoxin antibody made available that can be used with the antibiotics recommended for treatment of the disease. When exposure is suspected, raxibacumab should be given with anthrax vaccination to augment immunity. Raxibacumab provides additional protection against inhalational anthrax via a mechanism different from that of either antibiotics or active immunization. In combination with currently available and recommended therapies, raxibacumab should reduce the morbidity and mortality of inhalational anthrax.

Keywords: anthrax, monoclonal antibody, protective antigen, raxibacumab

Introduction

In December 2012, the United States Food and Drug Administration (FDA) approved raxibacumab for treatment of and prophylaxis against inhalational anthrax.¹ Its labeled uses are to treat inhalational anthrax in combination with appropriate antibacterial drugs, and for prophylaxis when alternative therapies are not appropriate or available.² For its approval, the FDA granted fast track designation, priority review, orphan product designation, and applied the Animal Efficacy Rule. Under this rule, medications are given FDA approval based on efficacy findings from adequate and well controlled animal studies when it is not feasible or ethical to conduct studies in human subjects.³ Inhalational anthrax is a rare and lethal disease, so efficacy studies are unethical and prohibited in humans.

After the bioterrorist attacks of September 2001, which resulted in eleven confirmed cases of inhalational anthrax and five fatalities, the US government enacted new rules and regulations to encourage pharmaceutical industry development of medical countermeasures against bioterrorist threats.⁴ The Project Bioshield Act was signed into law on July 2004 and provided funding for the development of raxibacumab.
Under Project Bioshield, the pharmaceutical company, Human Genome Sciences (GlaxoSmithKline, Research Triangle Park, NC, USA) was awarded a contract to develop and deliver human immune globulin against anthrax. The reason for commissioning the development of passive immunity is that current recommendations for therapy and exposure prophylaxis have limitations.

**Why is raxibacumab needed?**
Current therapy guidelines recommend use of antibiotics that are highly effective against *Bacillus anthracis*, but until recently did not recommend administration of antitoxin therapy. Patients die due to toxin-induced disease despite effective antibiotic use that kills the bacteria. Toxin levels are highest during initial presentation and decline with early antibiotic administration. The Anthrax Vaccine Adsorbed (BioThrax®; Emergent BioSolutions Inc., Rockville, MD, USA) licensed for use in the USA requires at least 4 weeks to develop sufficient protective immunity. Exposed patients are at risk of disease despite receiving immunization, given the bacteria’s short incubation period of at least 4 days after inhalation. Another concern is adherence with the recommended 2-month oral antibiotic regimens against exposure prophylaxis. In a study of antibiotic adherence among postal workers in Washington after the terrorist attacks of 2001, only 40% of those sampled reported full adherence, while another 18% had completely discontinued their prophylaxis. The US Centers for Disease Control and Prevention recently updated their guidelines in 2014 and support the use of antitoxin therapy (either raxibacumab or anthrax immune globulin) in combination with antimicrobial drug treatment in any patient for whom there is a high level of clinical suspicion for inhalational anthrax. They acknowledge that optimal timing of antitoxin administration remains unknown given the lack of data.

Thus, passive immunity in the form of protective antibodies has a role in treatment as well as post-exposure prophylaxis against inhalational anthrax. This review discusses raxibacumab (Abthrax®, GlaxoSmithKline), the first human monoclonal antibody approved for treatment and prophylaxis against inhalational anthrax.

**Pathophysiology of anthrax**
*B. anthracis* is a large rod-shaped, aerobic, Gram-positive, spore-forming bacterium that exists in a spore or vegetative state. The spore is the dormant form and is found in soils around the world. Anthrax spores are stable particles that can withstand very extreme conditions due to their highly coated and thick protein shell. This allows spores to survive in an adverse environment for prolonged periods of time.

The vegetative state is the replicating form that exists during active infection. Herbivore mammals typically acquire the infection after ingestion of spores, with transmission to humans upon contact with contaminated animal products.

Infection in humans results in four recognized forms of the disease, depending on the route of entry, ie, cutaneous, gastrointestinal, injection, and inhalational anthrax. Cutaneous anthrax is the most common and frequently resolves spontaneously. Initially, a painless or pruritic papule appears, and is surrounded by edema. The papule progresses to a vesicle, rupturing and creating an ulcer covered by a black eschar that sloughs 2–3 weeks later. Gastrointestinal anthrax occurs after ingestion of contaminated meat. Spores germinate, resulting in oropharyngeal and gastrointestinal ulceration, followed by regional lymphadenopathy, edema, sepsis, necrosis, and perforation. Ascites can also occur. Patients develop nausea, vomiting, bloody diarrhea, and ultimately pain resulting in an acute abdomen. Intravenous or intramuscular drug use results in injectional anthrax where the typical black eschar is absent. Patients develop subcutaneous lesions that lead to sepsis. Inhalational anthrax occurs after inhaled spores are phagocytosed by alveolar macrophages that carry the spores to hilar and mediastinal lymph nodes where they germinate. Germination results in hemorrhagic mediastinitis, bilateral hemorrhagic pleural effusions, dyspnea, hypotension, shock, and death. Patients initially present with influenza-like symptoms during the first 4 days, but rapidly progress to respiratory failure.

The anthrax genome is comprised of a single covalently closed chromosome. It contains two virulent plasmids, pXO1 and pXO2, responsible for synthesizing the immunologically inert capsule and the anthrax toxin, respectively. The capsule is composed of poly-γ-D-glutamyl amino acids and protects the bacteria from phagocytosis. The anthrax toxin is composed of two binary combinations, each containing a common binding component known as protective antigen (PA). The other two components, edema factor and lethal factor, are enzymes. PA combines with edema factor to form edema toxin, and in a similar way with lethal factor to form lethal toxin. PA is a protein that mediates binding to its receptors in the cell membrane of host cells. Binding to either a high-affinity or low-affinity receptor (ANTXR1/2) that may or may not require a coreceptor (LRP6) occurs, with subsequent transformation of PA, resulting in pore formation and facilitating translocation of edema factor and lethal factor into the cell cytosol (Figure 1). PA is therefore essential for intracellular translocation of both edema and lethal toxins. PA induces immunization, and all current acellular or attenuated live anthrax vaccines contain or express PA.
Edema factor is a calcium-dependent and calmodulin-dependent adenylate cyclase that increases intracellular levels of cyclic adenosine monophosphate. Lethal factor is a zinc metalloproteinase that inactivates mitogen-activated protein kinase kinases, resulting in impaired lymphocyte activation, B-cell proliferation, as well as macrophage apoptosis via activation of the cytosolic inflammasome pathway. A calcium-dependent and calmodulin-dependent adenylate cyclase increases intracellular cAMP, resulting in activation of cAMP response genes. Migration of infected macrophages to lymph nodes is stimulated, as well as inhibition of T-cell activation, impaired phagocytosis, oxidative burst, and cytokine dysregulation. cAMP induces vasodilation, leading to edema.

Abbreviations: LF, lethal factor; EF, edema factor; PA, protective antigen; LT, lethal toxin; ET, edema toxin; ANTXR1/2, low (ANTXR1, previously tumor endothelial marker) or high (ANTXR2, previously capillary morphogenesis protein) type 1 transmembrane receptors; LRP6, low-density lipoprotein receptor-related protein 6; MAPKK, mitogen-activated protein kinase kinases; CREB, cAMP response element binding protein; CRE, cAMP-response elements; cAMP, cyclic adenosine monophosphate.

Edema factor is a calcium-dependent and calmodulin-dependent adenylate cyclase that increases intracellular levels of cyclic adenosine monophosphate. Lethal factor is a zinc metalloproteinase that inactivates mitogen-activated protein kinase-kinase. Lethal toxin impairs both innate and adaptive immune reactions, leading to uncontrolled bacterial proliferation and cell death. Patients develop exudative pleural effusions. Lethal factor is a zinc metalloproteinase that inactivates mitogen-activated protein kinase-kinase. Lethal toxin impairs both innate and adaptive immune reactions, leading to uncontrolled bacterial proliferation and cell death. Patients develop

Figure 1 Pathophysiology of anthrax illustrated as a series of steps. 1) Bacillus anthracis spores germinate and release lethal factor and PA. Initially, PA is an 83 kDa monomer. 2) PA$_{83}$ binds to the ANTXR1/2 transmembrane receptors in the host cell. 3) Furin, a cell surface proprotein convertase, cleaves PA$_{83}$ into PA$_{20}$ and PA$_{63}$ fragments. The PA$_{20}$ fragment is cleaved off while PA$_{63}$ remains bound to the receptor. 4) Proteolytically processed PA$_{63}$ monomers assemble into a heptameric or octameric PA prepore. The PA prepore can bind up to three or four lethal factor or monomers. 5) Prepore clusters are internalized with or without the LRP6 coreceptor via receptor-mediated endocytosis, resulting in endosome formation. 6) Acidification of endosome results in prepore transformation into a transmembrane delivery pore. 7) Release of lethal factor and edema factor inside the cell. 8) Lethal factor, a zinc metalloproteinase, inactivates MAPKK, resulting in impaired lymphocyte activation, B-cell proliferation, as well as macrophage apoptosis via activation of the cytosolic inflammasome pathway. 9) A calcium-dependent and calmodulin-dependent adenylate cyclase increases intracellular cAMP, resulting in activation of cAMP response genes. Migration of infected macrophages to lymph nodes is stimulated, as well as inhibition of T-cell activation, impaired phagocytosis, oxidative burst, and cytokine dysregulation. cAMP induces vasodilation, leading to edema.
hemorrhagic mediastinitis from lymph node ulceration and septic shock.²⁶

Efforts directed at preventing anthrax toxin from entering the cell should avoid the deleterious effects of edema and lethal toxins. The most effective way to neutralize these toxins is to inhibit their common binding component, PA. Inhibition of PA would prevent its binding to the cell membrane and translocation of the toxin into the cell.

**Mechanism of action**

Raxibacumab is a recombinant human immunoglobulin G1λ monoclonal antibody that blocks the binding of PA to its cell receptor, thereby inhibiting pore formation and internalization of edema and lethal toxins (Figure 2).²²,²⁷,²⁸ The antibody was derived from a phage display library licensed by Human Genome Sciences from Cambridge Antibody Technology (AstraZeneca, London, UK). Raxibacumab binds to PA at the domain IV epitope with an affinity of 2.78±0.9 nM, and its inhibition is dose-dependent.²⁹,³⁰ Raxibacumab does not have any direct antibacterial activity. Therefore, it is advised that its use should be combined with the antibiotics recommended for the treatment of anthrax.

**Pharmacokinetics**

Raxibacumab shows linear pharmacokinetics over a dose range of 1–40 mg/kg after administration of a single intravenous dose. Serum levels can be detected for up to 56 days after administration. Raxibacumab has a mean half-life of 16–19 days, and has limited renal clearance. Its steady-state volume ranges from 58 mL/kg to 73 mL/kg, suggesting tissue distribution.³¹ Raxibacumab does not penetrate the blood–brain barrier.² When given with intravenous or oral ciprofloxacin, serum concentrations of neither medication are affected and the regimen is well tolerated.²⁷

**Dosage, administration, and safety**

In adults, raxibacumab is given as a single intravenous dose of 40 mg/kg over 2 hours and 15 minutes. The medication is diluted in 0.9% normal saline to give a total volume of 250 mL, and 25 mg or 50 mg of oral or intravenous diphenhydramine should be given within one hour to reduce the risk of infusion reactions.² The intravenous route is perceived as disadvantageous given that the intramuscular and subcutaneous routes are easier ways to administer the drug. A Phase I study showed that two intramuscular injection sites produced different bioavailabilities when compared with intravenous infusion.³¹ All studies evaluating the safety of raxibacumab have been done in adults (Table 1).²²,²⁷,³¹ The most common reactions reported during infusion included rash, urticaria, and pruritus. Other reactions included headache, upper respiratory tract infection, nausea, pain in arm or leg, cough, and arthralgias.²⁷ The following adverse reactions were seen more commonly with raxibacumab than placebo but occurred in less than 1.5% of subjects given raxibacumab: lymphadenopathy, palpitations, vertigo, fatigue, infusion site pain, peripheral edema, back pain, muscle spasms, vasovagal syncope, insomnia, flushing, and hypertension. Laboratory abnormalities seen after drug infusion included anemia, leukopenia, elevated amylase and creatine phosphokinase, and prolonged prothrombin time.² All adverse events resolved within the time period that safety studies were conducted.²⁷ Raxibacumab is considered a pregnancy category B medication (ie, no evidence of risk in animal studies, but no adequate human studies in pregnancy available).²²,²⁸

**Safety studies**

Four substudies were performed by Human Genome Sciences to assess the safety, tolerability, and pharmacokinetics of raxibacumab in healthy humans (Table 1). The first was a randomized, single-blind, placebo-controlled Phase I dose-escalation study conducted in 105 healthy volunteers.³¹ Subjects received placebo or raxibacumab as a single intramuscular injection or intravenous infusion. Three intramuscular and five intravenous dose levels were studied, along with two intramuscular injection sites. The
pharmacokinetics, half-life, and different bioavailabilities were calculated. This study showed that raxibacumab was safe, well tolerated, and bioavailable after a single intravenous or intramuscular dose. The second study was an open-label Phase I evaluation of the pharmacokinetics and safety of intravenous raxibacumab given at a dose of 40 mg/kg in combination with ciprofloxacin.27 Concomitant use of ciprofloxacin did not reduce the serum concentrations of either drug. The third study was a randomized, placebo-controlled comparison of a single dose of raxibacumab versus two doses of the drug.27 The results of this study were combined with those of the previous two studies and did not find significant differences in adverse reactions when compared with placebo. The fourth study was an open-label evaluation of the persistence of immunogenicity and safety with a repeat dose of intravenous raxibacumab at 4 months.27 The results of this last study have not yet been published. It is unethical and illegal to perform prophylactic and therapeutic efficacy studies in humans, so the majority of these studies have been performed in animals.

**Animal studies**

Prophylactic and therapeutic efficacy studies were conducted in rats, rabbits, and monkeys before raxibacumab received FDA approval (Table 2). Initial studies were conducted in rats, and two of these have been published. The first was a randomized, placebo-controlled study in which survival was evaluated at different time intervals after a 24-hour infusion of anthrax lethal toxin (PA plus lethal factor).32 Rats receiving raxibacumab within 6 hours of toxin administration had a better survival rate than those that received raxibacumab at 9 or 12 hours. In the same study, different doses of raxibacumab given 6 hours after toxin infusion were evaluated. The survival rate decreased with lower doses of raxibacumab. In the second study, rats were given a single injection of raxibacumab or placebo 24 hours before administration of the lethal toxin.27 The survival rate in rats that received the single raxibacumab dose was 100%, whereas that in rats that received placebo was 0%.

The positive outcomes of the above-mentioned studies led to further evaluation in animal models that better resemble humans. Rabbits are one of the preferred models of inhalational anthrax. In the first study, rabbits were given a single subcutaneous dose of raxibacumab 48 hours before exposure to anthrax spores on day 0 or a single 40 mg/kg intravenous raxibacumab dose immediately after exposure.29 Survival at 14 days was dose-dependent and significantly greater in the raxibacumab group than in the placebo group (which had a survival rate of 0%). Bacteremia was noted in all the rabbits that died but not in any of the rabbits given raxibacumab. The second study looked at therapeutic administration of raxibacumab after exposure.29 In the first experiment, a 40 mg/kg intravenous dose of raxibacumab was given at different time intervals starting at time 0 after exposure to anthrax spores. At 14 days post-exposure, all rabbits that had received raxibacumab at 0 and 12 hours were alive, whereas

<table>
<thead>
<tr>
<th>Study</th>
<th>Objective</th>
<th>Endpoint</th>
<th>Design</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Subramanian et al26</td>
<td>Safety</td>
<td>Pharmacokinetics, safety, and biological activity</td>
<td>105 subjects (80 raxibacumab, 25 placebo) IM (vastus lateralis or gluteus maximus) injection (0.3, 1, or 3 mg/kg) or placebo; IV injection (1, 3, 10, 20, or 40 mg/kg) or placebo</td>
<td>Half-life 15–19 days for IM and 16–19 days for IV injection; linear pharmacokinetics with both routes of administration. Higher bioavailability in IM vastus lateralis than gluteus maximus</td>
</tr>
<tr>
<td>Migone et al37</td>
<td>Safety</td>
<td>Safety and pharmacokinetics of concomitant administration with ciprofloxacin</td>
<td>88 subjects divided in three groups: raxibacumab plus ciprofloxacin (ciprofloxacin 500 mg orally every 12 hours for 6 days, then a single dose of raxibacumab on day 5); raxibacumab only (single dose on day 0), or ciprofloxacin only (400 mg IV every 12 hours on day 0, then 500 mg orally every 12 hours for 6 days)</td>
<td>No alterations in pharmacokinetics of raxibacumab or ciprofloxacin; safe to give both together</td>
</tr>
<tr>
<td>Migone et al37</td>
<td>Safety</td>
<td>14-day safety of additional dose and maintenance of drug serum levels</td>
<td>320 subjects (291 assigned to a single dose versus placebo; 29 assigned to a double dose at day 0 and day 14 versus placebo)</td>
<td>No significant difference in adverse reactions; no difference in serum levels of drug maintained at 28 days</td>
</tr>
<tr>
<td>Migone et al37</td>
<td>Safety</td>
<td>Four-month safety of additional booster dose</td>
<td>20 subjects who had already received raxibacumab given repeat “booster” at 4 months</td>
<td>Not published</td>
</tr>
</tbody>
</table>

**Abbreviations:** IM, intramuscular; IV, intravenous.
rabbits that received raxibacumab at 24 and 36 hours had 50% and 41.7% survival rates, respectively. In the second experiment, rabbits were exposed to anthrax spores and then given intravenous raxibacumab at different doses. The survival rate at 14 days post-exposure increased in rabbits that received higher doses, with 20 mg/kg and 40 mg/kg having the highest survival rates. The third study was an open-label, parallel-group, randomized, placebo-controlled study that randomized rabbits into three groups challenged with anthrax aerosol on day 0. Upon recording of body

### Table 2 Animal studies of raxibacumab

<table>
<thead>
<tr>
<th>Study</th>
<th>Species</th>
<th>Objective</th>
<th>Endpoint</th>
<th>Design</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rat</td>
<td>Cui et al27</td>
<td>Rat (Sprague-Dawley)</td>
<td>Post-exposure prophylaxis</td>
<td>324 rats exposed to 24-hour infusion of anthrax lethal toxin; raxibacumab was administered at time of, or 3, 6, 9 or 12 hours after initiation of infusion; raxibacumab given at different concentrations at 6 hours</td>
<td>Odds of survival greater for rats that received raxibacumab early; no difference from placebo when received at 9 and 12 hours; decrease in survival with lower concentrations of raxibacumab given 100% survival rate versus 0% for all three groups given raxibacumab, regardless of route of administration, when compared with placebo</td>
</tr>
<tr>
<td>Rabbit</td>
<td>Mazumdar29</td>
<td>Rabbit (New Zealand white)</td>
<td>Pre-exposure and post-exposure</td>
<td>72 rabbits divided into 6 groups (placebo or raxibacumab SC at 1, 5, 10, or 20 mg/kg; IV 40 mg/kg placebo or raxibacumab immediately post-exposure) exposed to anthrax spores</td>
<td>Higher survival rate in rabbits that received a higher dose</td>
</tr>
<tr>
<td>Rabbit</td>
<td>Migone et al27</td>
<td>Rabbit (New Zealand white)</td>
<td>Post-exposure treatment</td>
<td>Time-course experiment: 60 rabbits exposed to anthrax spores, then administered IV raxibacumab at time 0, 12, 24, or 36 hours post-exposure; controls given placebo at time 0.</td>
<td>Higher survival with earlier administration; higher survival at higher doses</td>
</tr>
<tr>
<td>Rabbit</td>
<td>Migone et al27</td>
<td>Rabbit (New Zealand white)</td>
<td>Post-exposure treatment</td>
<td>54 rabbits in three equal groups exposed to anthrax spores on day 0; if increase in temperature or detection of PA in blood, then given single dose of IV raxibacumab (20 mg/kg or 40 mg/kg) or placebo</td>
<td>Significantly greater survival for both raxibacumab groups than for placebo</td>
</tr>
<tr>
<td>Rabbit</td>
<td>Corey et al27</td>
<td>Rabbit (New Zealand white)</td>
<td>Post-exposure combined treatment</td>
<td>180 rabbits challenged with anthrax spores and then given intragastric levofloxacin (50 mg/kg daily) or levofloxacin plus IV raxibacumab (40 mg/kg) 84 hours post-exposure</td>
<td>24 survivors (65%) in levofloxacin group and 32 (82%) in levofloxacin plus raxibacumab (P=0.0874)</td>
</tr>
<tr>
<td>Monkey</td>
<td>Migone et al27</td>
<td>Monkey (Cynomolgus macaque)</td>
<td>Pre-exposure</td>
<td>40 monkeys randomized to single SC dose of placebo or raxibacumab (10, 20, or 40 mg/kg) 48 hours prior to anthrax spore exposure</td>
<td>22 monkeys that received raxibacumab survived (60% for 10 mg/kg, 70% for 20 mg/kg, and 90% for 40 mg/kg); all monkeys in the placebo group died before day 7 Greater survival for raxibacumab than placebo</td>
</tr>
<tr>
<td>Monkey</td>
<td>Migone et al27</td>
<td>Monkey (Cynomolgus macaque)</td>
<td>Post-exposure treatment</td>
<td>40 monkeys randomized to single IV raxibacumab (20 mg/kg or 40 mg/kg) or placebo after anthrax spore exposure given upon detection of PA in serum</td>
<td></td>
</tr>
</tbody>
</table>

**Abbreviations:** IgG, immunoglobulin; IM, intramuscular; IV, intravenous; SC, subcutaneous; PA, protective antigen.
temperature at least 1.1°C above baseline or detection of PA in serum, rabbits were given a single dose of raxibacumab (20 mg/kg or 40 mg/kg) or placebo. Survival at 14 days was significantly greater in the groups that received raxibacumab (28% for 20 mg/kg and 44% for 40 mg/kg) when compared with placebo (0%). The difference in survival between the two groups that received raxibacumab was not statistically significant. A fourth study evaluated the survival benefit of adding raxibacumab to levofloxacin versus levofloxacin alone 84 hours after inhalational exposure.31 Although the difference in survival rate did not reach statistical significance, it was higher in the group that received the combination of levofloxacin and raxibacumab. Half as many deaths occurred in the group that received combination treatment than in the group that received levofloxacin alone.

Monkeys are another preferred model of inhalational anthrax, given their close anatomic and genetic resemblance to humans. The initial study evaluated the efficacy of raxibacumab at different doses using a single subcutaneous injection 48 hours before exposure to spores.27 Monkeys that received higher doses had a greater likelihood of survival, the highest being achieved with the 40 mg/kg dose. Monkeys that survived were rechallenged with anthrax spores one year later, and all were protected. The second study was a single-blind, parallel-group, randomized, placebo-controlled evaluation of the therapeutic efficacy of raxibacumab after exposure to anthrax spores.27 Monkeys in this study received a single intravenous dose of raxibacumab (20 mg/kg or 40 mg/kg) or placebo after detection of PA in serum. The survival rate was higher at 28 days in both raxibacumab groups when compared with placebo.

These animal studies established that raxibacumab is effective against inhalational anthrax, and also demonstrated its effectiveness as a prophylactic agent. There seems to be protection against inhalational rechallenge one year after the initial exposure. Concomitant use with levofloxacin resulted in a clinically meaningful increase in survival 3.5 days after exposure. Raxibacumab adds an additional element of protection against inhalational anthrax not previously covered by antibiotics or vaccination.

Other similar antibodies
Six other monoclonal antibodies against PA are currently under investigation (Table 3),30 and neutralize PA via different mechanisms: inhibition of receptor binding (like raxibacumab); interference with transformation of PA into a heptamer when forming a pore in the cell membrane; and disruption of the preformed PA heptamer by formation of a supercomplex. Other monoclonal antibodies that are currently not in clinical use neutralize PA by interfering with lethal factor and binding or by blocking the enzymatic cleavage of PA into PA$_{20}$ and PA$_{30}$. Other monoclonal antibodies against PA have also been developed. Human anthrax immunoglobulin (Anthrivig™, Emergent BioSolutions Inc., Rockville, MD, USA) is derived from the plasma of humans immunized with Anthrax Vaccine Adsorbed vaccine and contains polyclonal antibodies against PA.34 Whether these other monoclonal and polyclonal antibodies are as effective as raxibacumab or provide advantages against inhalational anthrax remains to be determined.

Conclusion
Raxibacumab is a recombinant human monoclonal antibody that neutralizes anthrax toxins by inhibiting binding of PA to cell receptors. It is given intravenously as a single dose and its current FDA-approved indications include use as therapy for and prevention against inhalational anthrax.

To meet the FDA Animal Efficacy Rule requirements, raxibacumab has needed both human and animal studies to evaluate its safety and efficacy, respectively. Animals do not reflect human disease precisely. Therefore, different
animal models were developed in order to determine survival outcomes and extrapolate these to humans as precisely as possible. Under the current rules, efficacy need to be demonstrated in at least two different animal species. In addition, post-marketing human efficacy studies are mandated. Meeting these two requirements can be difficult and challenging. In the event of a bioterrorist attack, a post-marketing efficacy study would be a resource-intensive and difficult task to perform given the circumstances. Costly and timely resources have been invested in raxibacumab in order to receive FDA approval.

Current antibiotics or available anthrax vaccines do not provide antitoxin therapy like raxibacumab does. Whether future guidelines should incorporate passive immunity as part of the therapeutic armamentarium against inhalational anthrax needs to be discussed. This is important given the potential for anthrax to be used as a bioterrorist weapon. When combined with currently recommended antiantibiotics, as well as immunization when available, raxibacumab seems to be an effective therapy to combat the deleterious effects of anthrax toxins.

Acknowledgments
The author would like to thank Dr John T Huggins for reviewing the manuscript and Isabel Bonenfant for assistance in developing the figures.

Disclosure
The author reports no conflicts of interest in this work.

References


